Source: ERS Research Seminar



Rating:

Share or cite this content

Citations should be made in the following way:
Jacques Cadranel (Paris, France). EGFR TKI in the current clinical practice. ERS Research Seminar

Member's Comments

No comment yet.

Related content which might interest you: Re-purposing TKI treatment Source: International Congress 2016 – The future of tyrosin kinase inhibitors Year: 2016 Failure of EGFR TKI treatment: mechanisms and current strategies? Source: ERS Research Seminar Year: 2015 EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice Source: Eur Respir J, 50 (2) 1700514; 10.1183/13993003.00514-2017 Year: 2017 Comparison of NSCLC patient groups with activated EGFR mutations treated with three different tyrosine-kinase inhibitors (TKI): Real-life data from the Czech Republic Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside Year: 2017 Clinical experience on EGFR tyrosin kinase inhibitor in non-small-cell lung cancer, compassionate programme in the Czech Republic Source: Eur Respir J 2006; 28: Suppl. 50, 782s Year: 2006 Safety and tolerability of gefitinib in advanced NSCLC: overview of clinical experience Source: Eur Respir J 2003; 22: Suppl. 45, 32s Year: 2003 The future generations of TKIs Source: International Congress 2016 – The future of tyrosin kinase inhibitors Year: 2016 Uncommon EGFR mutations of lung adenocarcinoma in one tertiary institution, Korea: clinical characteristics and treatment response to tyrosine kinase inhibitors Source: International Congress 2018 – Lung cancer: from the bench to the bedside Year: 2018 KRAS oncogene in lung cancer: focus on molecularly driven clinical trials Source: Eur Respir Rev 2015; 25: 71-76 Year: 2016 Mutations of EGFR and k-ras genes and TK inhibitors. Are there differences between gefitinib and erlotinib? Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008 Dynamic monitoring of EGFR mutations in circulating tumor DNA for early detection of drug resistance in NSCLC patients on EGFR-TKI therapy Source: International Congress 2019 – Diagnostic procedures and biology of lung cancer Year: 2019 Clinical efficacy of 1st line EGFR-TKIs for NSCLC habouring EGFR mutation with high PD-L1 expression; A single-centered retrospective study Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer Year: 2020 The selective EGFR tyrosine-kinase inhibitor erlotinib in patients with advanced non-small-cell lung cancer (NSCLC) – a single institution experience of TRUST – a worldwide open label non randomized phase IV trial Source: Annual Congress 2007 - Therapy of lung cancer Year: 2007 Targeting STAT3 pathway signalling in EGFR TKI resistant NSCLC Source: Virtual Congress 2020 – Chronic lung diseases: novel methods, diagnostics and biomarkers Year: 2020 Potential therapeutic significance of CIK cells in gefitinib resistant NSCLC with EGFR mutations Source: Annual Congress 2011 - Progress in pathology of lung cancer Year: 2011 Therapeutic strategy for EGFR driven NSCLC Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine Year: 2019 Epidermal growth factor receptor (EGFR) gene mutation testing prior to tyrosine kinase inhibitors (TKI) treatment – prospective data from the Czech TULUNG registry Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology Year: 2020 Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors Source: ERJ Open Res, 3 (3) 00092-2016; 10.1183/23120541.00092-2016 Year: 2017 The importance of symptom improvement with gefitinib in NSCLC Source: Annual Congress 2004 - Gefitinib (Iressa) in NSCLC: A real alternative to chemotherapy Year: 2004